BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Phase I Study

Trial Profile

BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Phase I Study

Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Dec 2016

At a glance

  • Drugs Alpelisib (Primary) ; Capecitabine
  • Indications Rectal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Jun 2016 Status changed from not yet recruiting to recruiting.
    • 04 Mar 2016 Planned initiation date changed from 1 Dec 2015 to 1 Apr 2016, according to ClinicalTrials.gov record.
    • 19 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top